A combination of valproic acid sodium salt, CHIR99021, E-616452, tranylcypromine, and 3-Deazaneplanocin A causes stem cell-like characteristics in cancer cells.
A combination of valproic acid sodium salt, CHIR99021, E-616452, tranylcypromine, and 3-Deazaneplanocin A causes stem cell-like characteristics in cancer cells.
复制标题
丙戊酸钠盐、CHIR99021、E-616452、反苯环丙胺和 3-Deazaneplanocin A 的组合可在癌细胞中产生干细胞样特征
DOI:
10.18632/oncotarget.18396
复制
发表时间:
2017-08-08
期刊:
影响因子:
--
通讯作者:
Liu G
中科院分区:
文献类型:
--
作者:
Sha S;Zhai Y;Lin C;Wang H;Chang Q;Song S;Ren M;Liu G
Many studies are based on the hypothesis that recurrence and drug resistance in lung carcinoma are due to a subpopulation of cancer stem-like cells (CSLCs) in solid tumors. Therefore it is crucial to screen for and recognize lung CSLCs. In this study, we stimulated non-small cell lung cancer (NSCLC) A549 cells to display stem cell-like characteristics using a combination of five small molecule compounds. The putative A549 stem cells activated an important CSLC marker, CD133 protein, as well multiple CSLC-related genes including ATP-binding cassette transporter G2 (ABCG2), C-X-C chemokine receptor type 4 (CXCR4), NESTIN, and BMI1. The A549 stem-like cells displayed resistance to the chemotherapeutic drugs etoposide and cisplatin, epithelial-to-mesenchymal transition properties, and increased protein expression levels of NOTCH1 and Hes Family bHLH Transcription Factor 1 (HES1). When A549 cells were pretreated with a NOTCH signaling pathway inhibitor before compound induction, expression of the NOTCH1 target gene HES1 was reduced. This demonstrated that the NOTCH signaling pathway in the putative A549 stem-like cells had been activated. Together, the results of our study showed that a combination of five small molecule agents could transform A549 cells into putative stem-like cells, and that these compounds could also elevate CD133 and ABCG2 protein expression levels in H460 cells. This study provides a convenient method for obtaining lung CSLCs, which may be an effective strategy for developing lung carcinoma treatments.
登录
查看更多内容
DOI:
10.1074/jbc.m114.548651
发表时间:
2014-03-21
期刊:
The Journal of biological chemistry
影响因子:
--
作者:
Fujiwara T;Saitoh H;Inoue A;Kobayashi M;Okitsu Y;Katsuoka Y;Fukuhara N;Onishi Y;Ishizawa K;Ichinohasama R;Harigae H
通讯作者:
Harigae H
DOI:
10.1111/resp.12094
发表时间:
2013-07
期刊:
Respirology (Carlton, Vic.)
影响因子:
--
作者:
Alamgeer M;Peacock CD;Matsui W;Ganju V;Watkins DN
通讯作者:
Watkins DN
影响因子:
3.7
作者:
Levina V;Marrangoni AM;DeMarco R;Gorelik E;Lokshin AE
通讯作者:
Lokshin AE
影响因子:
23.9
作者:
Ichida JK;Blanchard J;Lam K;Son EY;Chung JE;Egli D;Loh KM;Carter AC;Di Giorgio FP;Koszka K;Huangfu D;Akutsu H;Liu DR;Rubin LL;Eggan K
通讯作者:
Eggan K
影响因子:
5.8
作者:
Greenblatt, David Yu;Vaccaro, Abram M.;Chen, Herbert
通讯作者:
Chen, Herbert